Interventions for chronic non-hypovolaemic hypotonic hyponatraemia

Area of Science:

• Nephrology
• Endocrinology
• Internal Medicine

Background:

• Chronic non-hypovolaemic hypotonic hyponatraemia is common and linked to poorer health outcomes.
• Existing treatments like fluid restriction and vasopressin receptor antagonists aim to correct hyponatraemia, but their impact on patient well-being is unclear.

Purpose of the Study:

• To evaluate the benefits and harms of interventions for chronic non-hypovolaemic hypotonic hyponatraemia.
• To determine if treatment effects vary based on drug class, dosage, or underlying cause.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
• Included studies compared interventions against placebo, no treatment, or other interventions.
• Data extraction and risk of bias assessment were performed independently by two authors.

Main Results:

• Vasopressin receptor antagonists likely increase serum sodium concentration but also raise the risk of rapid correction and side effects like thirst and polyuria.
• Evidence for effects on mortality and health-related quality of life is of very low certainty.
• A potential reduction in hospital stay was observed, but data are limited.

Conclusions:

• Vasopressin receptor antagonists offer a modest increase in serum sodium at the cost of increased risk of rapid correction and uncertain patient-important outcomes.
• Treatment decisions should weigh the benefits of sodium level increase against short-term risks and unknown long-term effects.
• Further research is needed, particularly on standard treatments and patient-important outcomes.